Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06467136 · ClinicalTrials.gov registry record · NA

Motor Imagery for Treatment Enhancement and Efficacy in Persons With Apraxia of Speech

A NA study of Apraxia of Speech and Apraxia, Oral, sponsored by University of Central Florida.

Recruiting
Registry status
NA
Development phase
18
Enrollment target
1
Study location

NCT06467136: Recruiting NA study of Apraxia of Speech and Apraxia, Oral, sponsored by University of Central Florida.

NCT06467136 is a NA study of Apraxia of Speech and Apraxia, Oral that is actively recruiting participants, run by University of Central Florida. The registered enrollment target is 18 participants, below the 39-participant average among 5 other Apraxia of Speech trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06467136, a NA study of Apraxia of Speech and Apraxia, Oral, is actively recruiting participants, sponsored by University of Central Florida.

RECRUITING
Registry status
NA
Development phase
18 participants
Enrollment target
1
Study location

Study Summary

Treatment of post-stroke apraxia of speech (AOS) requires frequent and ongoing practice with a speech-language pathologist to facilitate lasting behavioral change, which is costly and, therefore, inaccessible to many patients. Thus, there is a critical need to identify novel, cost-effective ways to supplement speech therapy to increase opportunities for practice and optimize treatment outcomes. Our long-term goal is to develop an effective, home-practice, computer-based, motor imagery protocol Motor Imagery for Treatment Enhancement and Efficacy (MI-TEE) which will serve as an adjunct to routine speech therapy to optimize treatment response in persons with AOS. The overall objectives of this application are to (i) evaluate the acceptability and feasibility of MI-TEE as a home practice program and (ii) determine the efficacy of MI-TEE with speech therapy, compared to speech therapy alone, in improving speech production in people with AOS. Our central hypothesis is that MI-TEE will be an accessible, feasible, and efficacious adjunct to speech therapy. To attain our objectives, the following specific aims will be pursued using two single-subject experimental designs with multiple baselines across participants (n=18): 1) Evaluate the acceptability and feasibility of MI-TEE as an adjunct to speech therapy for the rehabilitation of AOS; and 2) Compare the efficacy of adjunctive MI-TEE plus standard speech therapy to standard speech therapy alone. Under the first aim, observational data, surveys, and semi-structured interviews will be employed to assess the acceptability (perceived satisfaction, appropriateness, and intent to continue use) and feasibility (recruitment, retention, and intervention adherence rates) of MI-TEE. For the second aim, accuracy of articulation for trained words and untrained words (generalization) will be measured pre-treatment, repeatedly during the treatment phase, and post-treatment. Improvements in speech accuracy will be documented using a bin

Interventions

  • BEHAVIORAL Sound production treatment
  • BEHAVIORAL Motor Imagery Practice

Study Locations (1)

Florida

  • University of Central Florida Innovation Rehabilitation Center - Orlando

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2023-12-11
Est. Completion 2026-07-31
Phase NA
University of Central Florida

91 total trials

What NCT06467136 shows while recruiting

NCT06467136 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 39-participant average among 5 other Apraxia of Speech trials with a reported enrollment target (54% lower).

The record links to 2 conditions, with Apraxia of Speech appearing as the primary indexed condition, and to 2 interventions - of which Sound production treatment is the first listed.

NCT06467136 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT06467136 about?

NCT06467136 is a clinical study titled "Motor Imagery for Treatment Enhancement and Efficacy in Persons With Apraxia of Speech". Treatment of post-stroke apraxia of speech (AOS) requires frequent and ongoing practice with a speech-language pathologist to facilitate lasting behavioral change, which is costly and, therefore, inaccessible to many patients. Thus, there is a critical need to identify novel, cost-effective ways to ...

What is the current status of trial NCT06467136?

This trial is currently recruiting. It is a NA study. The enrollment target is 18 participants. The study started on 2023-12-11. Estimated completion is 2026-07-31.

What conditions does trial NCT06467136 study?

This clinical trial studies the following conditions: Apraxia of Speech, Apraxia, Oral.

What interventions are being tested in trial NCT06467136?

The interventions under investigation include: Sound production treatment (BEHAVIORAL), Motor Imagery Practice (BEHAVIORAL).

Who is sponsoring clinical trial NCT06467136?

This trial is sponsored by University of Central Florida, which has 91 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06467136 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Apraxia of Speech

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01245179 · 18 participants · Phase 1

    Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

  • NCT01999361 · 18 participants · NA

    Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

  • NCT02359825 · 18 participants · Phase 1

    Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function

  • NCT02870244 · 18 participants · Phase 1

    Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06467136, the US trial registry maintained by the National Library of Medicine. NCT06467136 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.